These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24293756)

  • 1. Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia.
    Ratti E; Carpenter DJ; Zamuner S; Fernandes S; Squassante L; Danker-Hopfe H; Archer G; Robertson J; Alexander R; Trist DG; Merlo-Pich E
    Sleep; 2013 Dec; 36(12):1823-30. PubMed ID: 24293756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of gaboxadol on sleep in adult and elderly patients with primary insomnia: results from two randomized, placebo-controlled, 30-night polysomnography studies.
    Lankford DA; Corser BC; Zheng YP; Li Z; Snavely DB; Lines CR; Deacon S
    Sleep; 2008 Oct; 31(10):1359-70. PubMed ID: 18853933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of vestipitant with ondansetron for the treatment of breakthrough postoperative nausea and vomiting after failed prophylaxis with ondansetron.
    Kranke P; Thompson JP; Dalby PL; Eberhart LH; Novikova E; Johnson BM; Russ SF; Noble R; Brigandi RA
    Br J Anaesth; 2015 Mar; 114(3):423-9. PubMed ID: 25488303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia.
    Krystal AD; Durrence HH; Scharf M; Jochelson P; Rogowski R; Ludington E; Roth T
    Sleep; 2010 Nov; 33(11):1553-61. PubMed ID: 21102997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
    Rosenberg R; Murphy P; Zammit G; Mayleben D; Kumar D; Dhadda S; Filippov G; LoPresti A; Moline M
    JAMA Netw Open; 2019 Dec; 2(12):e1918254. PubMed ID: 31880796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study.
    Murphy P; Moline M; Mayleben D; Rosenberg R; Zammit G; Pinner K; Dhadda S; Hong Q; Giorgi L; Satlin A
    J Clin Sleep Med; 2017 Nov; 13(11):1289-1299. PubMed ID: 29065953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
    Roth T; Soubrane C; Titeux L; Walsh JK;
    Sleep Med; 2006 Aug; 7(5):397-406. PubMed ID: 16815744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study.
    Scharf M; Rogowski R; Hull S; Cohn M; Mayleben D; Feldman N; Ereshefsky L; Lankford A; Roth T
    J Clin Psychiatry; 2008 Oct; 69(10):1557-64. PubMed ID: 19192438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of Dimdazenil in the adult insomnia patients: a phase II randomized, multicenter, double-blind, placebo-controlled, and parallel-group study.
    Li Y; Zhang R; Zhou Y; Bao C; Lin Z; Chen C; He J; Jin Z; Song L; Zhang M; Guo S; Jiang Y; Zhao Z
    Sleep; 2024 Feb; 47(2):. PubMed ID: 37864827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study.
    Krystal AD; Erman M; Zammit GK; Soubrane C; Roth T;
    Sleep; 2008 Jan; 31(1):79-90. PubMed ID: 18220081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia.
    Krystal AD; Lankford A; Durrence HH; Ludington E; Jochelson P; Rogowski R; Roth T
    Sleep; 2011 Oct; 34(10):1433-42. PubMed ID: 21966075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference.
    Black J; Pillar G; Hedner J; Polo O; Berkani O; Mangialaio S; Hmissi A; Zammit G; Hajak G
    Sleep Med; 2017 Aug; 36():86-94. PubMed ID: 28735928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia.
    Bettica P; Squassante L; Zamuner S; Nucci G; Danker-Hopfe H; Ratti E
    Sleep; 2012 Aug; 35(8):1097-104. PubMed ID: 22851805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia.
    Connor KM; Mahoney E; Jackson S; Hutzelmann J; Zhao X; Jia N; Snyder E; Snavely D; Michelson D; Roth T; Herring WJ
    Int J Neuropsychopharmacol; 2016 Aug; 19(8):. PubMed ID: 26979830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of Dimdazenil in adults with insomnia disorder: results from a multicenter, randomized, double-blind, placebo-controlled phase III trials.
    Huang Z; Zhan S; Chen C; Zhang R; Zhou Y; He J; Lin Z; Bao C; Zhu S; Zhao J; Zhang S; Jiang Y; Wang Y
    Sleep; 2024 Feb; 47(2):. PubMed ID: 37875349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled, multicenter, 28-day, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance.
    Furey SA; Hull SG; Leibowitz MT; Jayawardena S; Roth T
    J Clin Sleep Med; 2014 Oct; 10(10):1101-9. PubMed ID: 25317091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why receptor reserve matters for neurokinin1 (NK1) receptor antagonists.
    Trist DG; Ratti E; Bye A
    J Recept Signal Transduct Res; 2013 Dec; 33(6):333-7. PubMed ID: 24106886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia.
    Roth T; Rogowski R; Hull S; Schwartz H; Koshorek G; Corser B; Seiden D; Lankford A
    Sleep; 2007 Nov; 30(11):1555-61. PubMed ID: 18041488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study.
    Roth T; Krystal A; Steinberg FJ; Singh NN; Moline M
    Sleep; 2013 Feb; 36(2):189-96. PubMed ID: 23372266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial.
    Fietze I; Bassetti CLA; Mayleben DW; Pain S; Seboek Kinter D; McCall WV
    Drugs Aging; 2022 Oct; 39(10):795-810. PubMed ID: 36098936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.